PJP
Invesco Pharmaceuticals ETF
Price Chart
Latest Quote
$119.37
+2.29 (+1.96%)
Current Price
| Previous Close | $117.08 |
| Open | $117.73 |
| Day High | $119.80 |
| Day Low | $117.50 |
| Volume | 45,130 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.90% |
| Shares Outstanding | 6.30M |
| Net Assets | $356.15M |
| Expense Ratio | 0.57% |
| Category | Health |
| Fund Family | Invesco |
| Net Asset Value | $119.42 |
| Premium/Discount | -0.04% |
| Quarterly Dividend Yield | 0.90% |
| P/E Ratio | 21.78 |
| Exchange | PCX |
📊 ETF Analysis
Company Data
| Book/sh | $96.83 |
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 1.24 |
Analyst Data
Technical Indicators
| SMA20 | $117.72 |
| SMA50 | $112.35 |
| SMA200 | $105.09 |
| RSI | 52.96 |
| ATR | 1.8814 |
| Rel Volume | 0.28 |
Performance History
| Week | +0.98% |
| Month | +6.30% |
| Quarter | +14.25% |
| 6 Months | +13.89% |
| YTD | +15.31% |
| Year | +45.35% |
| 3 Years | +66.33% |
| 5 Years | +56.11% |
| 10 Years | +98.64% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $119.71 | 13,200 |
| 2026-07-16 | $119.37 | 45,300 |
| 2026-07-15 | $117.08 | 57,100 |
| 2026-07-14 | $115.91 | 221,000 |
| 2026-07-13 | $117.60 | 424,600 |
| 2026-07-10 | $118.55 | 5,500 |
| 2026-07-09 | $120.45 | 8,500 |
| 2026-07-08 | $120.94 | 8,100 |
| 2026-07-07 | $122.24 | 6,500 |
| 2026-07-06 | $120.09 | 9,500 |
| 2026-07-02 | $120.91 | 11,600 |
| 2026-07-01 | $117.57 | 11,200 |
| 2026-06-30 | $118.45 | 11,500 |
| 2026-06-29 | $118.62 | 20,900 |
| 2026-06-26 | $118.67 | 26,200 |
| 2026-06-25 | $115.68 | 4,800 |
| 2026-06-24 | $114.90 | 6,800 |
| 2026-06-23 | $114.09 | 8,300 |
| 2026-06-22 | $112.14 | 23,300 |
| 2026-06-18 | $111.36 | 26,300 |
About Invesco Pharmaceuticals ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
📰 Latest News
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks • 2026-06-29T10:20:02Z
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks • 2026-05-21T10:20:02Z
Pharma's $370B Bet on America: The ETF Plays for 2026
Zacks • 2025-12-19T17:15:00Z
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
Zacks • 2025-12-09T18:40:00Z
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Zacks • 2025-11-14T12:59:00Z
Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?
Zacks • 2025-11-10T12:47:00Z
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio
Zacks • 2025-10-06T10:57:00Z
AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?
Barchart • 2025-08-05T12:57:19Z
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks • 2025-07-22T10:20:06Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.